╌>

Experimental Ebola Vaccine Tested in Guinea Shows Promise, Report Says

  

Category:  News & Politics

Via:  dr-trevor-k-johnson  •  11 years ago  •  4 comments

Experimental Ebola Vaccine Tested in Guinea Shows Promise, Report Says

Experimental Ebola Vaccine Tested in Guinea Shows Promise, Report Says

JULY 31, 2015

Link to NYT source article

A woman receiving an Ebola vaccination in Guinea in March. The clinical trial involved inoculating people who had come into contact with Ebola patients, and the contacts of those contacts.

An experimental Ebola vaccine being tested in the West African nation of Guinea during the continuing outbreak of the viral disease has shown promising initial results, according to a report on the clinical trial that was published on Friday.

The report, published in the British medical journal The Lancet, which analyzed 7,651 individuals, more than 3,500 of whom were vaccinated, indicated that the vaccine might be highly efficacious and safe in preventing Ebola virus disease.

This is good news, Dr. Margaret Chan, director general of the World Health Organization , said in an interview, while noting that the vaccine was not a silver bullet to head off future outbreaks. There is no replacement for very strong and good, resilient health systems with the capability for surveillance, she said.

Dr. Sakoba Keita, Guineas Ebola response coordinator and one of the studys authors, said in an email that Guineans hoped the results would contribute to the rapid control of the next epidemics caused by this disease.

The clinical trial involved inoculating people who had come into contact with Ebola patients, and the contacts of those contacts. Some clusters of people were vaccinated immediately, while others, assigned randomly, were vaccinated only after 21 days, the maximum incubation period of the virus.

After 10 days, none of those who had been immediately vaccinated subsequently contracted Ebola, whereas 16 of the people eligible for the study who were not immediately vaccinated came down with the disease. The analysis was started at Day 10 to give the vaccine time to set off an immune response , and because some of the contacts might already have been incubating the virus.

Those results were highly significant, the authors reported, indicating the vaccine was 75 to 100 percent efficacious. In fact, the researchers observed that there were no Ebola cases in any vaccinated patients after the first six days.

The results are very encouraging, said Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, who was not involved in the trial, which he called a very difficult study under very difficult circumstances. He added that the studys unorthodox design makes it difficult to get the precise information you need, but that, even in the absence of that, the results are impressive.

Another hope was that vaccinating many of those closest to an Ebola patient might quickly shut down a local outbreak, even among those not vaccinated. Despite tantalizing signs of effectiveness, the findings did not reach statistical significance, perhaps in part because roughly a third of those eligible for immediate vaccination did not consent to participate. In addition, the vaccine was not given to children or pregnant women because its safety in those populations was not yet known.

Because no placebos were used, volunteers knew whether they had received the vaccine, which could have influenced the studys outcome. Choices like this, some of which were highly contentious on ethical and scientific grounds, were made to be pragmatic in the context of an emergency, said Jeremy Farrar, director of the Wellcome Trust, a major supporter of the research.

The fact that promising results were obtained in spite of certain compromises in scientific rigor, he said, in a sense vindicates the design and approach that was taken and moves the field forward.

Some outbreak responders initially opposed the idea of carrying out research in the midst of a dire emergency, but Dr. Farrar said this was imperative.

You cant test these things in a period between epidemics, he said. He and other experts said better and faster approaches to conducting research in outbreaks were needed.

This was the first time in memory that a vaccines effectiveness has been studied with a so-called ring vaccination approach, inoculating all of those around the occurrence of an infectious disease, according to one of the studys senior authors, Dr. John-Arne Rottingen of the Norwegian Institute of Public Health. That vaccination strategy was used to help eradicate smallpox .

I thought the only way to be successful would be to follow the epidemic and try to vaccinate in high-risk individuals, Dr. Rottingen said in an interview. This approach ended up producing results even when the country had only a small number of cases, distributed across a large area.

The clinical trial in Guinea has been more successful than we almost could have hoped for, Dr. Rottingen said.

Continue reading at NY Times


Tags

jrDiscussion - desc
[]
 
screminmimi
Freshman Silent
link   screminmimi    11 years ago

As I posted on the other article about this vaccine...

There could have been a vaccine decades ago but it wasn't needed, as the people affected by the disease were "just" jungle inhabitants, black villagers no one cared about.

Now that the mighty "African Summit Meeting" has been held and billions of dollars are being invested by the US government, RCA, and other corporations in the rich African resources... now that infrastructure has to be built and workers have to be assured they are in no danger of contracting the infamous disease, and these workers will be flying back and forth from Africa to the US and other countries on a routine basis and containment of another outbreak would be impossible....

we have a vaccine developed in record short time, clinical trials fast-tracked, assurances that it is 100% effective. This is amazing. In my ignorance, I was under the impression that no vaccine is 100% effective, that exceptions can happen even if they occur "once in a blue moon."

 
 
 
Petey Coober
Freshman Silent
link   Petey Coober    11 years ago

Thanks for posting this info Doctor J. It sounds promising even though there may have been a flaw in the study due to it not being properly controlled .

One thing I wonder about is does it protect against pockets of virus that hide in various locations [the eye for example] . The issue of infection spread could be affected by that .

 
 
 
Perrie Halpern R.A.
Professor Guide
link   Perrie Halpern R.A.    11 years ago

Mimi,

I don't think that it is 100% effective, especially since we are talking about a relatively small clinical trial. In the article it says:

Those results were highly significant, the authors reported, indicating the vaccine was 75 to 100 percent efficacious. In fact, the researchers observed that there were no Ebola cases in any vaccinated patients after the first six days.

What I find annoying about this, is that when the medical community feels so moved, they seem to come up with a cure.

This could also apply to AIDS. The only other animals known to get AIDS other than primates, are cats. Yet with cats, they have a vaccine to prevent the disease. Given that the first people to get it were gay / intravenous drug users, very little incentive to do something about it. Even less now, since they have a cocktail of drugs that net big pharm big money. Same thing with the HPV vaccine. It makes big pharm billions. Here is a creepy fact about it. It was never tested on the age group that it's given to, because it is unethical to test on minors. Strange that it isn't unethical to give it to them. We will not know if it affected the reproductive systems for about another 10 years.

Now please don't get me wrong, I am very glad that they have come up with this vaccine. What I would like to know, is if they are going to inoculate poor Africans?

 
 
 
Sophia Descertes
Freshman Silent
link   Sophia Descertes    11 years ago

I hope this works because from what I have seen on the news, ebola is a very nasty disease..

 
 

Who is online





72 visitors